{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"3.29","upperLimit":"3.29","value":"3.29"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"Duration of response is defined as the time from the first documented evidence response (CR or PR lasting 4 months for CTCL; and CR, marrow CR, CRp, Cri or PR for MDS) until the first documented disease progression or death due to any cause. Median and inter-quartile range (first quartile and third quartile) of duration of response are presented.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Participants Cutaneous T cell lymphoma (CTCL) were administered once daily oral dose of 60 mg GSK525762.","id":"OG000","title":"Part 2: GSK525762 60 mg QD CTCL"},{"description":"Participants with Myelodysplastic Syndrome (MDS) were administered once daily oral dose of 75 mg GSK525762","id":"OG001","title":"Part 2: GSK525762 75 mg QD MDS"},{"description":"Participants CTCL were administered once daily oral dose of 80 mg GSK525762","id":"OG002","title":"Part 2: GSK525762 80 mg QD CTCL"}],"paramType":"MEDIAN","populationDescription":"All treated Population. Only those participants with data available at the specified data points were analyzed. Participants with incomplete response rates were excluded from the analysis hence N=0 for 60 mg QD and 80 mg QD CTCL arms.","reportingStatus":"POSTED","timeFrame":"Up to 36.4 weeks","title":"Part 2: Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"Months"}